
PRA Health Sciences, Inc. Revenue | PRAH
Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.
Traditionally defined as follows:Revenue = Price * Quantity of productsRevenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]
This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.
Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.
Annual Revenue PRA Health Sciences, Inc.
| 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|
| 3.18 B | 3.07 B | 2.87 B | 2.26 B | 1.81 B | 1.61 B | 1.46 B | - | 700 M | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 3.18 B | 700 M | 2.12 B |
References
- Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).
Revenue of other stocks in the Diagnostics research industry
| Issuer | Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Enzo Biochem
ENZ
|
31.9 M | - | -8.98 % | $ 14.8 K | ||
|
Renalytix AI plc
RNLX
|
2.29 M | - | 5.66 % | $ 22.7 M | ||
|
DexCom
DXCM
|
4.66 B | $ 82.53 | 0.6 % | $ 32.2 B | ||
|
Meridian Bioscience
VIVO
|
333 M | - | - | $ 1.49 B | ||
|
Heska Corporation
HSKA
|
257 M | - | - | $ 1.31 B | ||
|
Accelerate Diagnostics
AXDX
|
11.7 M | - | -61.36 % | $ 2.46 M | ||
|
T2 Biosystems
TTOO
|
7.19 M | - | -39.35 % | $ 313 K | ||
|
Syneos Health
SYNH
|
5.39 B | - | - | $ 4.46 B | ||
|
Biocept
BIOC
|
25.9 M | - | -13.05 % | $ 7.29 M | ||
|
Invitae Corporation
NVTA
|
122 M | - | - | $ 21.2 M | ||
|
Quotient Limited
QTNT
|
38.5 M | - | -11.32 % | $ 1.1 M | ||
|
DermTech
DMTK
|
15.3 M | - | -11.32 % | $ 2.94 M | ||
|
Surmodics
SRDX
|
126 M | - | - | $ 608 M | ||
|
Brainsway Ltd.
BWAY
|
41 M | $ 9.02 | -1.04 % | $ 306 M | ||
|
Akumin
AKU
|
750 M | - | -17.87 % | $ 25.9 M | ||
|
Psychemedics Corporation
PMD
|
19.7 M | - | -1.84 % | $ 15.3 M | ||
|
Danaher Corporation
DHR
|
24.6 B | $ 228.43 | 1.18 % | $ 163 B | ||
|
Chembio Diagnostics
CEMI
|
49.5 M | - | 0.22 % | $ 16.8 M | ||
|
Motus GI Holdings
MOTS
|
319 K | - | -34.28 % | $ 263 K | ||
|
HTG Molecular Diagnostics
HTGM
|
6.37 M | - | -20.0 % | $ 1.06 M | ||
|
Anixa Biosciences
ANIX
|
210 K | $ 2.72 | 1.87 % | $ 88.3 K | ||
|
Biodesix
BDSX
|
88.5 M | $ 8.42 | -5.18 % | $ 63.6 M | ||
|
Agilent Technologies
A
|
6.95 B | $ 176.32 | 2.38 % | $ 50.1 B | ||
|
BioNano Genomics
BNGO
|
28.5 M | $ 0.98 | 3.13 % | $ 5.34 M | ||
|
Burning Rock Biotech Limited
BNR
|
540 M | $ 12.85 | 2.8 % | $ 135 M | ||
|
Bioventus
BVS
|
568 M | $ 10.64 | 0.38 % | $ 709 M | ||
|
Quest Diagnostics Incorporated
DGX
|
11 B | $ 259.18 | 1.1 % | $ 28.8 B | ||
|
Charles River Laboratories International
CRL
|
4.02 B | $ 333.37 | 0.36 % | $ 16.5 B | ||
|
Guardant Health
GH
|
982 M | $ 145.11 | 1.28 % | $ 18.2 B | ||
|
Castle Biosciences
CSTL
|
344 M | $ 33.41 | 1.3 % | $ 968 M | ||
|
Illumina
ILMN
|
4.34 B | $ 209.18 | 3.24 % | $ 32.4 B | ||
|
IQVIA Holdings
IQV
|
16.3 B | $ 257.93 | 0.13 % | $ 44.3 B | ||
|
Laboratory Corporation of America Holdings
LH
|
14 B | $ 370.49 | 0.61 % | $ 30.8 B | ||
|
IDEXX Laboratories
IDXX
|
4.3 B | $ 700.79 | 1.53 % | $ 56.4 B | ||
|
Medpace Holdings
MEDP
|
2.53 B | $ 647.03 | -0.93 % | $ 18.7 B | ||
|
Mettler-Toledo International
MTD
|
4.03 B | $ 1 734.36 | 1.25 % | $ 35.7 B | ||
|
Natera
NTRA
|
2.31 B | $ 286.77 | -0.25 % | $ 39.2 B | ||
|
Lantheus Holdings
LNTH
|
1.54 B | $ 102.03 | 0.23 % | $ 6.89 B | ||
|
Fulgent Genetics
FLGT
|
323 M | $ 25.14 | 3.84 % | $ 774 M | ||
|
CareDx, Inc
CDNA
|
380 M | $ 74.4 | -0.21 % | $ 3.96 B | ||
|
Oxford Immunotec Global PLC
OXFD
|
73.7 M | - | - | $ 562 M | ||
|
Biomerica
BMRA
|
4.45 M | $ 1.15 | -6.88 % | $ 3.35 M | ||
|
Interpace Biosciences
IDXG
|
38.7 M | $ 5.44 | -9.42 % | $ 24.1 M | ||
|
Fluidigm Corporation
FLDM
|
138 M | - | 1.08 % | $ 308 M | ||
|
ICON Public Limited Company
ICLR
|
8.25 B | $ 194.96 | -0.03 % | $ 15.3 B | ||
|
Senseonics Holdings
SENS
|
35.3 M | $ 9.76 | -3.99 % | $ 407 M | ||
|
Sotera Health Company
SHC
|
1.16 B | $ 16.27 | 1.34 % | $ 4.62 B | ||
|
Co-Diagnostics
CODX
|
622 K | $ 0.2 | 1.99 % | $ 266 K | ||
|
Precipio
PRPO
|
24 M | $ 18.8 | -1.93 % | $ 30.2 M |